Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: Continued experience of a phase I trial in rectal cancer patients [18]

Christopher G. Willett, Yves Boucher, Dan G. Duda, Emmanuelle Di Tomaso, Lance L. Munn, Ricky T. Tong, Sergey V. Kozin, Lucine Petit, Rakesh K. Jain, Daniel C. Chung, Dushyant V. Sahani, Sanjeeva P. Kalva, Kenneth S. Cohen, David T. Scadden, Alan J. Fischman, Jeffrey W. Clark, David P. Ryan, Andrew X. Zhu, Lawrence S. Blaszkowsky, Paul C. ShellitoMari Mino-Kenudson, Gregory Y. Lauwers

Research output: Contribution to journal › Article

344 Citations (Scopus)
Original languageEnglish (US)
Pages (from-to)8136-8139
Number of pages4
JournalJournal of Clinical Oncology
Volume23
Issue number31
DOIs
StatePublished - 2005

Fingerprint

Drug Dose Response Relationship
Radiotherapy Dosage
Antineoplastic Combined Chemotherapy Protocols
Pathologic Neovascularization
Combined Modality Therapy
Maximum Tolerated Dose
Rectal Neoplasms
Fluorouracil
Biomarkers
Monoclonal Antibodies
Radiation
Drug Therapy
Therapeutics
Bevacizumab

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy : Continued experience of a phase I trial in rectal cancer patients [18]. / Willett, Christopher G.; Boucher, Yves; Duda, Dan G.; Di Tomaso, Emmanuelle; Munn, Lance L.; Tong, Ricky T.; Kozin, Sergey V.; Petit, Lucine; Jain, Rakesh K.; Chung, Daniel C.; Sahani, Dushyant V.; Kalva, Sanjeeva P.; Cohen, Kenneth S.; Scadden, David T.; Fischman, Alan J.; Clark, Jeffrey W.; Ryan, David P.; Zhu, Andrew X.; Blaszkowsky, Lawrence S.; Shellito, Paul C.; Mino-Kenudson, Mari; Lauwers, Gregory Y.

In: Journal of Clinical Oncology, Vol. 23, No. 31, 2005, p. 8136-8139.

Research output: Contribution to journal › Article

Willett, CG, Boucher, Y, Duda, DG, Di Tomaso, E, Munn, LL, Tong, RT, Kozin, SV, Petit, L, Jain, RK, Chung, DC, Sahani, DV, Kalva, SP, Cohen, KS, Scadden, DT, Fischman, AJ, Clark, JW, Ryan, DP, Zhu, AX, Blaszkowsky, LS, Shellito, PC, Mino-Kenudson, M & Lauwers, GY 2005, 'Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: Continued experience of a phase I trial in rectal cancer patients [18]', Journal of Clinical Oncology, vol. 23, no. 31, pp. 8136-8139. https://doi.org/10.1200/JCO.2005.02.5635
Willett CG, Boucher Y, Duda DG, Di Tomaso E, Munn LL, Tong RT et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: Continued experience of a phase I trial in rectal cancer patients [18]. Journal of Clinical Oncology. 2005;23(31):8136-8139. https://doi.org/10.1200/JCO.2005.02.5635
Willett, Christopher G. ; Boucher, Yves ; Duda, Dan G. ; Di Tomaso, Emmanuelle ; Munn, Lance L. ; Tong, Ricky T. ; Kozin, Sergey V. ; Petit, Lucine ; Jain, Rakesh K. ; Chung, Daniel C. ; Sahani, Dushyant V. ; Kalva, Sanjeeva P. ; Cohen, Kenneth S. ; Scadden, David T. ; Fischman, Alan J. ; Clark, Jeffrey W. ; Ryan, David P. ; Zhu, Andrew X. ; Blaszkowsky, Lawrence S. ; Shellito, Paul C. ; Mino-Kenudson, Mari ; Lauwers, Gregory Y. / Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy : Continued experience of a phase I trial in rectal cancer patients [18]. In: Journal of Clinical Oncology. 2005 ; Vol. 23, No. 31. pp. 8136-8139.
@article{6577c5335bf74bb9b89a07e8aa9adf4a,
title = "Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: Continued experience of a phase I trial in rectal cancer patients [18]",
author = "Willett, {Christopher G.} and Yves Boucher and Duda, {Dan G.} and {Di Tomaso}, Emmanuelle and Munn, {Lance L.} and Tong, {Ricky T.} and Kozin, {Sergey V.} and Lucine Petit and Jain, {Rakesh K.} and Chung, {Daniel C.} and Sahani, {Dushyant V.} and Kalva, {Sanjeeva P.} and Cohen, {Kenneth S.} and Scadden, {David T.} and Fischman, {Alan J.} and Clark, {Jeffrey W.} and Ryan, {David P.} and Zhu, {Andrew X.} and Blaszkowsky, {Lawrence S.} and Shellito, {Paul C.} and Mari Mino-Kenudson and Lauwers, {Gregory Y.}",
year = "2005",
doi = "10.1200/JCO.2005.02.5635",
language = "English (US)",
volume = "23",
pages = "8136--8139",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "31",

}

TY - JOUR

T1 - Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy

T2 - Continued experience of a phase I trial in rectal cancer patients [18]

AU - Willett, Christopher G.

AU - Boucher, Yves

AU - Duda, Dan G.

AU - Di Tomaso, Emmanuelle

AU - Munn, Lance L.

AU - Tong, Ricky T.

AU - Kozin, Sergey V.

AU - Petit, Lucine

AU - Jain, Rakesh K.

AU - Chung, Daniel C.

AU - Sahani, Dushyant V.

AU - Kalva, Sanjeeva P.

AU - Cohen, Kenneth S.

AU - Scadden, David T.

AU - Fischman, Alan J.

AU - Clark, Jeffrey W.

AU - Ryan, David P.

AU - Zhu, Andrew X.

AU - Blaszkowsky, Lawrence S.

AU - Shellito, Paul C.

AU - Mino-Kenudson, Mari

AU - Lauwers, Gregory Y.

PY - 2005

Y1 - 2005

UR - http://www.scopus.com/inward/record.url?scp=30944452436&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30944452436&partnerID=8YFLogxK

U2 - 10.1200/JCO.2005.02.5635

DO - 10.1200/JCO.2005.02.5635

M3 - Article

C2 - 16258121

AN - SCOPUS:30944452436

VL - 23

SP - 8136

EP - 8139

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 31

ER -

Access to Document